Face-to-face consortium meeting 2025 and field visit in Benin
- europevaccine
- Jun 6
- 2 min read
Partners of the ADVANCE_VAC4PM project and members of its Scientific and ethics advisory committee (SEAC) met at La Fondation pour la Recherche Scientifique (FORS) in Cotonou, Benin on 28-29 May 2025 to discuss the latest progresses towards the clinical evaluation of the PRIMVAC and PAMVAC-cVLP placental malaria vaccine candidates. GMP manufacturing of both antigens is currently ongoing along with the preparation of the phase Ia/Ib clinical trial to be conducted at Radboudumc (The Netherlands) and GRAS (Burkina Faso).
June 2025
Further discussions focused on other complementary activities in the project:
Creation of electronic pregnancy registers and qualitative assessment of a mobile app to monitor pregnancy outcomes: focus group discussions and in-depth interviews with health workers and pregnant women have been successfully completed at the four African sites (KHRC, Ghana; GRAS, Burkina Faso; FORS, Benin and MUST, Malawi) and data analysis is ongoing. Preliminary results from the qualitative assessment at KHRC were presented.
Assessing the potential cost-effectiveness of placental malaria vaccine introduction in Malawi using health economic modelling: the study has been completed, and preliminary results were presented by the MUST team. Further discussion among project partners on the study assumptions will strengthen the final data analysis and preparation for publication.
Stakeholder engagement activities: the workshop on “Strategy to use malaria vaccines to prevent malaria in pregnancy” is in its final stage of preparation and is set to be held on 03 June 2025.
Special thanks to our partners and SEAC members for the very productive discussion.
The meeting at FORS concluded with a visit to Dangbo Hospital in Dangbo, Ouémé, which is used by FORS as a field site for the mobile app qualitative assessment and for preparing future clinical activities related to placental malaria vaccine candidates.
Contact details:
Dr. Flavia D’Alessio (Project Leader)
Email: flavia.dalessio@euvaccine.eu
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.
Comments